News | January 13, 2025
Aragen secures $100 million investment from Quadria Capital
Investment will fund expansion to meet rising demand for CRDMO services
Investment will fund expansion to meet rising demand for CRDMO services
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Executes the first project for developing and manufacturing a novel anticancer mAb
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
